Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥361.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥28.14B
Enterprise Value¥24.81B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Debt / Strong Balance SheetZero or negligible debt gives J‑TEC durable financial flexibility to fund R&D, regulatory work, and manufacturing scale without interest burden. This reduces refinancing risk during cash‑flow variability and supports multi-year regenerative medicine development cycles and capex needs.
Diversified Regenerative Medicine Revenue StreamsJ‑TEC’s mix of approved product sales plus contract manufacturing/processing and R&D services creates multiple, structurally different revenue channels. This diversification ties the firm to both clinical demand and outsourcing trends in cell therapy, supporting recurring institutional customers.
Strong Revenue Growth And Healthy Gross MarginsSubstantial top‑line growth combined with high gross margins indicates product-market fit and pricing power in core products. Sustained revenue expansion with strong gross profitability provides runway to absorb operating investments and achieve operating leverage if cost control stabilizes.
Bears Say
Inconsistent ProfitabilityThe swing from profit to loss demonstrates volatile earnings driven by operating cost swings and execution challenges. Persistent profitability inconsistency undermines long‑term planning, makes internal funding less reliable, and raises the need for recurring external capital to sustain growth.
Negative Operating & Free Cash FlowRepeated negative operating and free cash flow indicate the business is not consistently self‑funding, elevating reliance on external financing or equity issuance. That constrains strategic investments, increases dilution or liquidity risk, and stresses execution during multi‑year product commercialization.
Weak Capital Efficiency (ROE Turned Negative)A negative ROE despite a sizable equity base signals poor conversion of shareholder capital into returns. Over time this pressures management to improve margins or reallocate capital; failure to lift ROE risks long‑term investor returns and could limit access to favorable financing.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥361.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥28.14B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is May 01, 2026 which is in 33 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jan 30, 2026. The company reported -¥4.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.56.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.